Inducing apoptosis in castration- resistant prostate cancer by targeting sphingomyelin synthase 1 for mono and combination therapy
Active Project Grant Awarded Last action
- Award ID
- R16GM159673
- Recipient
-
Idaho State University UEI JJC9GJJJL4M7
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $277,088
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date 30% complete
- Place of performance
- Pocatello, ID 83209, USA
Award details come from USAspending.gov.
Description
- Abstract
- In aging men ≥ 65 years, prostate cancer (PC) is the most common cancer especially for treatment evading resistant variants. The goal of this project is to develop ceramide mimics based sphingomyelin synthase 1 (SMS1) inhibitors for the treatment of castration-resistant prostate cancer (crpc) by preventing ceramide (CER) metabolism. Upregulation of ceramide-metabolizing enzymes, included with concomitant reduction in cellular ceramide levels, is observed in aggressive cancers, including crpc. This activity is also associated with increased resistance to apoptosis and with biosynthesis of secondary metabolites that promote cell survival. Strategies that increase ceramide thus hold potential for treatment of refractory cancers. Targeting ceramide metabolism in-conjunction with FDA approved pharmacological interventions has promise in treating crpc. Ceramide mimic - jaspine b, a naturally-occurring ceramide mimic, inhibits sphingomyelin synthase (SMS) - a key ceramide-metabolizing enzyme. In a team effort, our laboratory identified jaspine b exhibited dose-dependent cytotoxicity against melanoma and sarcoma cells in culture that was associated with increased caspase-3/7 activity. Jaspine b also displayed marked therapeutic efficacy in our in vivo synovial sarcoma model. These strong preliminary data support a medicinal chemistry program to improve the drug-like properties of molecules. The efficacy of jaspine b in crpc will be validated in two well characterized prostate cancer cell lines and in a relevant patient-derived xenograph (PDX) mouse model. The goals of the proposed research are to: 1) evaluate the efficacy of SMS1 inhibition by jaspine b in crpc. 2) improve jaspine b- mediated SMS1 inhibition through analog synthesis and/or combination therapy. 3) delineate the possible mechanisms of resistance of SMS1 inhibition. The completion of the project will identify a lead molecule based on jaspine b core targeting SMS1 in crpc, identify a probe to interrogate ceramide flux. The major innovation of this project is the therapeutic development of sphingolipid membrane biochemistry using the ceramide mimic jaspine b core. We aim to show the significance of sphingolipids in combination therapy with FDA approved anticancer agents. This project will have a significant impact on undergraduate and graduate student training at idaho state university.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $138,411 | |
| Original award | $138,677 |
Quick answers
Who received award R16GM159673?
R16GM159673 was awarded to Idaho State University by National Institute of General Medical Sciences (National Institutes of Health) on September 1, 2025.
How much is award R16GM159673 worth?
$277,088 has been obligated on R16GM159673.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award